Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507782 | 0.84 | NOTUM (0.72) | NOTUMSIRT2CYP1A2NPC1RAB9A | |
| SCHEMBL2107628 | 0.82 | NPC1 (0.64) | NOTUMSIRT2NPC1RAB9AHTT | |
| SCHEMBL12617891 | 0.82 | NOTUM (0.64) | NOTUMCYP1A2NPC1RAB9ATSHR | |
| SCHEMBL201423 | 0.82 | NOTUM (0.56) | NOTUMSIRT2CYP1A2NPC1RAB9A | |
| SCHEMBL10937283 | 0.82 | SIRT2 (0.71) | NOTUMSIRT2CYP1A2NPC1RAB9A | |
| SCHEMBL10904042 | 0.82 | SMN1; SMN2 (0.59) | NPC1RAB9ATSHRHTTSMN1; SMN2 | |
| SCHEMBL26009685 | 0.82 | NOTUM (0.56) | NOTUMSIRT2CYP1A2NPC1RAB9A | |
| SCHEMBL28869610 | 0.82 | SIRT2 (0.51) | NOTUMSIRT2CYP1A2NPC1RAB9A | |
| SCHEMBL8592557 | 0.82 | ACACB (0.59) | NOTUMSIRT2CYP1A2NPC1RAB9A | |
| SCHEMBL31049642 | 0.82 | NOTUM (0.70) | NOTUMSIRT2CYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093377-B | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2023-04-07 | — | — | CN | claimed |
| CN-115093377-A | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2022-09-23 | — | — | CN | claimed |
| US-20240300932-A1 | N-PHENYLIMINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | GUIZHOU UNIVERSITY (CN) | 2024-09-12 | — | — | US | disclosed |
| WO-2024174317-A1 | N-PHENYLIMINE-CONTAINING DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 贵州大学 | 2024-08-29 | — | — | WO | disclosed |
| US-11970470-B1 | {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents | King Faisal University (SA) | 2024-04-30 | — | — | US | disclosed |
| CN-116731003-A | N-phenylimine-containing derivative, and preparation method and application thereof | 贵州大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11718592-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-08 | — | — | US | disclosed |
| CN-115093377-B | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-115093377-A | Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof | 贵州大学 | 2022-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300932-A1 | N-PHENYLIMINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | PNMT, NNMT, PAH | NOTUM 443/4885SIRT2 358/4885CYP1A2 95/4885 |
| US-11718592-B2 | Oxadiazole derivative | OXA1L, SCN1A, CACNA1A | NOTUM 3472/4885SIRT2 291/4885CYP1A2 43/4885 |
| US-11970470-B1 | {5-chloro-2-(2-(3-(substitutedphenyl)-1,2,4-oxadiazol-5-yl)ethyl)phenyl}(phenyl)methanones as larvicidal agents | CASP3, CASP2, CASP7 | NOTUM 1319/4885SIRT2 2822/4885CYP1A2 57/4885 |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | OXA1L, SCN1A, CACNA1A | NOTUM 3472/4885SIRT2 291/4885CYP1A2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.